Introduction
============

Lung cancer has the highest incidence rate of cancer and becomes the leading cause of cancer death (about 1.38 million deaths annually) in the world ([@B39]; [@B46]). The estimated new cases and deaths from lung cancer in the United States in 2016 were 224,390 and 158,080, respectively ([@B2]). Non-small cell lung cancer (NSCLC) comprises 80∼85% of lung cancer cases, with an extremely poor 5-year survival rate of \<15% and only 5∼10% survival rate for advanced NSCLC ([@B34]). Despite considerable advances in lung cancer therapy, including chemotherapy, radiotherapy, and immunotherapy, the overall success in treating NSCLC remains unsatisfactory due to the limited efficacy and/or serious side effects ([@B32]; [@B16]). Therefore, much attention has been focused on anti-cancer agents derived from herbal medicines to change the unsatisfactory situation, owing to their extensive efficacy and low toxicity.

Green tea, the fresh leaves from the evergreen plant *Camellia sinensis* (L.) O. Kuntze (Theaceae), is the most ancient health-promoting beverage in the world. It has been officially described as a medicine by the earliest national pharmacopeia '*Xin Xiu Ben Cao'* (Newly Revised Materia Medica, AD 659) in Tang Dynasty of China, and was characterized with bitter and sweet flavor as well as cold and non-toxic nature, which can function to eliminate the heat, phlegm, and toxins from body. In the traditional Chinese medicine (TCM) theory, heat, phlegm and toxins are considered as causes of many chronic diseases, such as cancer, resulting in the application of green tea by TCM for the prevention/treatment of cancer ([@B50]). In recent years, the anti-cancer activity of green tea, especially against lung cancer, has been evidenced by various studies ([@B15]; [@B51]; [@B3]; [@B42]). As the main pigments of green tea, theabrownin (TB), theaflavin (TF) and thearubigin (TR) together determine the color, taste, and the bioactivity of the tea liquor ([@B35]). Of these pigments, TB is a major fraction governing the medicinal effects of green tea, such as cholesterol-lowering effect in relieving fatigue and reducing blood lipid levels ([@B9]). In view of the TB's key role in green tea, it can be expected that TB has a certain anti-lung cancer potential representative for the same activity of green tea. However, whether it does is unknown yet.

Cell proliferation is dependent on the progression of the cell cycle which is composed of the G~1~, S, G~2~ and M phases, and the transition from the G~1~ to S phase is critical as it controls the subsequent progress of the cell cycle ([@B26]). The G~1~ to S phase transition is tightly regulated by the activation of CDKs, which act consecutively in G~1~ to initiate the S phase and in the G~2~ phase to initiate mitosis ([@B8]; [@B24]). Previous studies have reported that many natural products could inhibit cell cycle progression (G~0~/G~1~ arrest) and proliferation of the NSCLC cells (A549 cell line), indicating G~0~/G~1~ checkpoint in cell cycle as one of the most conspicuous targets for anti-cancer agents. For determining the anti-lung cancer effect of TB, this study employed A549 cells and conducted cellular and molecular assays to evaluate TB's effect on cell cycle progression and proliferation of the NSCLC cells and explore the underlying mechanism.

Materials and Methods {#s1}
=====================

Chemicals and Materials
-----------------------

Theabrownin powders (\>90% of purity) and green tea crude extract were provided by Theabio Co., Ltd (Hangzhou, China; Batch number: 20151105001). Roswell Park Memorial Institute (RPMI) 1640 medium, fetal bovine serum (FBS), and 0.25% trypsin were obtained from Gibco BRL (Grand Island, NY, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and dimethyl sulfoxide (DMSO) were obtained from Sigma (St. Louis, MO, USA). Cell cycle kit was obtained from BD Biosciences (San Jose, CA, USA). All antibodies were purchased from Cell Signaling Technology (CST, Danvers, MA, USA). Trizol reagent and real time polymerase chain reaction (real time PCR) kit were purchased from TaKaRa (Dalian, China). Transferase dUTP nick-end labeling (TUNEL) staining kit was purchased from Roche Applied Science (Indianapolis, IN, USA).

Cell Line and Animal
--------------------

Human NSCLC A549 cell line and mouse Lewis lung carcinoma (LLC) cell line were obtained from Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China) and cultured in RPMI-1640 medium containing 10% FBS at 37°C in a humidified 5% CO~2~ incubator. The medium was changed daily and the cells were used in their logarithmic growth phase. Male C57BL/6 mice weighing 20∼22 g were purchased from Shanghai Laboratory Animal Center of Chinese Academy of Sciences (Grade SPF II, SCXK2012-0002) and housed under controlled pathogen-free conditions with a 12 h light/dark cycle and allowed food and water *ad libitum*. All animals were treated in strict accordance with the China legislation on the use and care of laboratory animals. The animal experiment was approved by the Medical Norms and Ethics Committee of Zhejiang Chinese Medical University.

MTT Assay
---------

MTT assay was performed to evaluate the cell viability of A549 cells, as described in our previous report ([@B47]). Cells were seeded on 96-well plates with density of 5 × 10^3^ cells/well in 200 μl medium for 24 h and then treated with TB at different concentrations (0, 5, 25, 50, 100, 150, 200, 300 μg/ml) for 24, 48, and 72 h. Each 20 μl MTT solution (5.0 mg/ml) was added to each well and incubated at 37°C for 4 h. Then 150 μl DMSO was added in each well to dissolve the MTT formazan crystals and the optical density value (OD value) was measured at 490 nm with a microplate reader (Bio-Rad, Berkeley, CA, USA). Inhibitory rate (%) = \[1- (TB - treated OD / untreated OD)\] × 100%. The 50% inhibitory concentrations (IC~50~) for 24, 48, and 72 h were calculated by regression analysis, respectively.

Cell Cycle Analysis
-------------------

Cell cycle analysis was performed with flow cytometry, as described in our previous report ([@B47]). Briefly, A549 cells were seeded on 6-well plates with density of 3 × 10^5^ cells/well for 24 h, followed by TB treatment for 24, 48, and 72 h. The cells were harvested and washed with PBS thrice and suspended in cold phosphate-buffered saline. Cells were then stained with PI/RNase staining solution (20 μg/ml PI, 10 μg/ml DNase free RNase) at 37°C in dark for 30 min. The cell cycle was analyzed in three replicates using flow cytometry (Beckman Coulter, USA).

Real Time PCR Analysis
----------------------

After TB treatment, gene expression in A549 cells was detected by real time PCR assay on an ABI QuantStudio^TM^ 7 Flex Real-Time PCR System (Applied Biosystems, Foster City, CA, USA), according to our previous report ([@B47]). The total RNA of the cells in each group was extracted using Trizol reagent and synthesized to cDNA via reverse transcription. PCR reaction system had a 20.0 μl volume: 10.0 μl SYBR^®^ Premix Ex Taq II (Tli RnaseH Plus), 0.8 μl PCR Forward Primer, 0.8 μl PCR Reverse Primer, 2.0 μl template cDNA, 0.4 μl ROX Reference Dye, and 6.0 μl ddH~2~O. The qPCR reaction condition was set to 95°C for 30 s initial denaturation, 40 cycles of 95°C for 5 s denaturation, 60°C for 34 s annealing, and 72°C for 40 s extension. At the end of each reaction, a melting curve analysis was performed. β-actin was used as the reference gene and 2^-ΔΔCT^ method was applied to analyze the relative expression of gene *C-MYC* (forward: GCCACGTCTCCACACATCAG; backward: TGGTGCATTTTCGGTTGTTG), *CYCLIN D* (forward: CAATGACCCCGCACGATTTC; backward: CATGGAGGGCGGATTGGAA), *CYCLIN A* (forward: GGATGGTAGTTTTGAGTCACCAC; backward: CACGAGGATAGCTCTCATACTGT), *P21* (forward: GGCAGACCAGCATGACAGATT; backward: GCGGATTAGGGCTTCCTCT), *P27* (forward: TGGAGAAGCACTGCAGAGA; backward: GCGTGTCCTCAGAGTTAGCC), *CDK2* (forward: GCTAGCAGACTTTGGACTAGCCA; backward: AGCTCGGTACCACAGGGTCA), *CDK4* (forward: AAATCTTTGACCTGATTGGG; backward: CCTTATGTAGATAAGAGTGCTG), *PCNA* (forward: GTAGTAAAGATGCCTTCTGGTG; backward: TCTCTATGGTAACAGCTTCCTC), and *PTEN* (forward: CCGAAAGGTTTTGCTACCATTCT; backward: AAAATTATTTCCTTTCTGAGCATTCC).

Western Blot Analysis
---------------------

Following TB treatment, A549 cells were harvested and washed thrice with cold PBS. As previously described ([@B47]), the cell pellets were resuspended in cell lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton, 0.1% SDS, 5 μg/ml leupeptin, and 1 mM PMSF) for 30 min on ice repeated freezing and thawing for three times. After cold centrifugation at 14,000 r/min for 20 min, the supernatant was collected and stored at -80°C. The lysed protein was quantified using a BCA protein assay kit. Appropriately 20 μg of lysed protein was boiled in 4x sample buffer and separated by a denaturing SDS-PAGE (8∼12%). The gels were transferred onto polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA) and blocked with 5% non-fat milk for 2 h, followed by overnight incubation at 4°C with the primary antibodies: c-Myc, Cyclin A, Cyclin D, P21, P27, Cdk2, Cdk4, proliferation of cell nuclear antigen (PCNA), phosphate and tension homolog (PTEN), and β-tubulin. Following incubation with peroxidase-conjugated goat anti-rabbit IgG at room temperature for 2 h, proteins were visualized using enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Little Chalfont, UK) and detected using a chemiluminescence analyzer.

Lewis Lung Carcinoma (LLC)-Bearing Mouse Model Establishment and TB Treatment
-----------------------------------------------------------------------------

To establish the lung cancer model of mouse, LLC cells (1.0 × 10^7^ cells in 0.1 ml of PBS) were injected subcutaneously into 40 mice. The mice were randomly divided into four groups of 10 mice each: model group, low-dose TB group, middle-dose TB group, and high-dose TB group. After the injection, mice in the low-dose TB, middle-dose TB, and high-dose TB groups were daily treated with 0.1 g/kg, 0.2 g/kg, and 0.4 g/kg mice body weight by oral administration for 21 days, respectively.

Evaluation of *In vivo* Anti-tumor Effect of TB
-----------------------------------------------

Mouse body weight of each mouse in each group was measured per 3 days, and the tumor growth was observed for recording tumor incidence. On day 21, all mice were sacrificed and each tumor was sampled for size and weight measurement. The tumor volume was estimated by the formula ([@B12]):

V

(

m

m

3

)

=

(

l

e

n

g

t

h

×

w

i

d

t

h

2

)

2

.

*In situ* Apoptosis Assay
-------------------------

As previously described, the tumor tissue in each mouse was dissected, fixed in 10% formaldehyde for 24 h, and embedded in paraffin wax. Sections (2∼3 μm) were stained by terminal deoxynucleotidyl TUNEL using the *in situ* cell death detection kit (Roche) according to the manufacturer's instructions to detect the apoptotic cells ([@B53]). Apoptotic cells were manifested by green staining in the nuclei under microscopy and five microscopic fields (×400) of each section were randomly examined, and the positive cells were counted by a single-blinded observer in a coded randomized order.

Statistical Analysis
--------------------

Data were expressed as mean ± SD and subjected to one-way ANOVA, followed by Fisher's least significant difference (LSD) comparison. All analyses were performed using an updated version of DPS software ([@B44]).

Results
=======

TB Inhibits Cell Viability of A549 Cells
----------------------------------------

As shown by MTT assay in **Figure [1](#F1){ref-type="fig"}**, TB treatment caused an obvious inhibition of A549 cell viability at various concentrations (5∼300 μg/ml) for 24, 48, and 72 h. The inhibitory effect was increased with increasing concentrations at each time point and was also increased with increasing time period at each concentration point, indicating a dose- and time-dependent manner of TB. The IC~50~ values were 239.89 ± 13.78, 145.80 ± 33.67, and 63.93 ± 35.44 μg/ml for 24, 48, and 72 h treatment, respectively. The green tea extract could also induce cell viability inhibition at the same concentration range for 24, 48, and 72 h, but the effect was weaker than that of TB. The 200 μg/ml was selected as a high effective dose of TB for the following assays.

![**Effect of Theabrownin (TB) and green tea extract on cell viability of A549 cells determined by MTT assay.** Values were presented as mean ± SD (*n* = 5).](fphar-08-00075-g001){#F1}

TB Induces Cell Cycle Arrest at G~0~/G~1~ Phase in A549 Cells
-------------------------------------------------------------

As shown by flow cytometry in **Figure [2](#F2){ref-type="fig"}**, TB-treated A549 cells was accumulated in the G~0~/G~1~ phase of the cell cycle, with a significant increase of cell number in the G~0~/G~1~ phase as compared to controls (all *P* \< 0.05). Correspondingly, the number of cells in the S phase and G~2~/M phase were significantly decreased except for that in the G~2~/M phase at 24 h. These trends indicated that TB could induce cell cycle arrest of A549 cells in G~0~/G~1~ phase.

![**Effect of TB on cell cycle of A549 cells determined by flow cytometry.** Values were presented as mean ± SD (*n* = 3). ^∗^*P* \< 0.05 and ^∗∗^*P* \< 0.01 for comparison between control group and TB group.](fphar-08-00075-g002){#F2}

TB Modulates Cell Cycle Associated mRNA and Protein Expression
--------------------------------------------------------------

As shown by real time PCR in **Figure [3](#F3){ref-type="fig"}**, the mRNA expression of cell cycle associated genes were significantly modulated by TB (200 μg/ml) after 24 to 72 h treatment. Of these genes, *C-MYC. CYCLIN A. CYCLIN D. CDK2. CDK4*, and *PCNA* were down-regulated while *P21. P27*, and *PTEN* were up-regulated, as compared to the control. Mostly, the modulation effect of TB on those genes displayed a time-dependent manner. In accordance with this result, western blot analysis also showed a similar trend of protein expressions encoded by those genes (**Figure [4](#F4){ref-type="fig"}**).

![**Relative mRNA expression of target genes in A549 cells with TB treatment at 200 μg/ml for 24, 48, and 72 h.** Values are presented as mean ± SD of three replicates. Different symbols (a, ab, b, c, bc, d) indicate significant difference between groups \[Fisher's least significant difference (LSD), *P* \< 0.05\], and the values decrease with the order from a to d.](fphar-08-00075-g003){#F3}

![**Protein expression of target genes in A549 cells with TB treatment at 200 μg/ml for 24, 48, and 72 h**.](fphar-08-00075-g004){#F4}

*In vivo* Anti-tumor Effect of TB
---------------------------------

As shown in **Figure [5](#F5){ref-type="fig"}**, the mice body weight in LLC model group was gradually changed after LLC injection and even decreased after day 9. In TB-treated groups, the mice body weight kept increase with a dose dependent manner of TB treatment, suggesting a recovery of physiological state induced by TB. In each group, LLC tumor growth could be visually seen at day 9 and the tumor incidence among all groups were differed, in which the model group had the highest incidence but the TB-treated groups had lesser ones (**Table [1](#T1){ref-type="table"}**). On day 21, the tumor volume in the model group was significantly bigger than that in the TB-treated groups, showing that TB could significantly inhibit the LLC growth in a dose-dependent manner (**Figure [6](#F6){ref-type="fig"}**). TUNEL assay also showed a consistent result that TB could induce remarkable apoptosis in LLC tumors in a dose-dependent manner (**Figure [7](#F7){ref-type="fig"}**).

![**Mice body weight of all groups (*n* = 10)**.](fphar-08-00075-g005){#F5}

###### 

Tumor incidence (%) of Lewis lung carcinoma (LLC)-bearing mouse model with TB treatment (*n* = 10).

                   Day1   Day3   Day5   Day7   Day9   Day11   Day13   Day15   Day17   Day19   Day21
  ---------------- ------ ------ ------ ------ ------ ------- ------- ------- ------- ------- -------
  Normal           0      0      0      0      0      0       0       0       0       0       0
  Model            0      0      0      0      90     100     100     100     100     100     100
  Low-dose TB      0      0      0      0      40     70      100     100     100     100     100
  Middle-dose TB   0      0      0      0      10     50      90      100     100     100     100
  High-dose TB     0      0      0      0      10     40      100     100     100     100     100
                                                                                              

![**Tumor volume of mice in all groups (*n* = 10).** Different symbols (a, ab, bc, c) indicate significant difference between groups (Fisher's LSD, *P* \< 0.05), and the values decrease with the order from a to c. Bar = 1 cm.](fphar-08-00075-g006){#F6}

![**Transferase dUTP nick-end labeling (TUNEL) and DAPI staining on mice tumors and the TUNEL-positive cell number comparison among all groups.** Different symbols (a, b, c, d) indicate significant difference between groups (Fisher's LSD, *P* \< 0.05), and the values decrease with the order from a to d.](fphar-08-00075-g007){#F7}

Discussion
==========

There has been a growing interest in ethnopharmacological use of TCMs as a new strategy for anti-cancer treatment, owing to their advantages of high bioactivities and low toxicity. As the most common beverage and also a TCM, green tea was found with anti-cancer activity against e.g., lung cancer. A 10-year epidemiological survey on 8,552 individuals has concluded that over 10 cups of green tea per day could delay the cancer onset among the general population ([@B30]). The need of drinking over 10 cups means that the anti-cancer effect of green tea may rely on the accumulation of some kind of low-content component. Thus, to find out what component dominates the anti-cancer effect of green tea is of practical necessity, so that it can be concentrated and developed into an efficient agent for cancer treatment. In the present study, we focused on the anti-cancer effect and the underlying mechanism of TB on NSCLC cells, in view of the fact that green tea has anti-NSCLC effect and TB acts as its main component ([@B35]; [@B20]; [@B52]).

Our results demonstrated that TB inhibited A549 cell viability in a dose- and time-dependent manner and blocked A549 cell cycle at G~0~/G~1~ phase (**Figure [1](#F1){ref-type="fig"}**). The real time PCR and western blot analyses have clarified the associated mechanism that TB induced cell cycle arrest through down-regulation of c-myc, cyclin A, cyclin D, cdk2, cdk4, PCNA and up-regulation of p21, p27, and PTEN (**Figure [2](#F2){ref-type="fig"}**). The c-myc is a transcriptional factor and a well known oncogene expressed in G~1~ phase of cell cycle, which induces DNA synthesis by direct control of the initiation of DNA replication or by transcriptional regulation of the genes involved in DNA replication ([@B7]). Dysfunctional overexpression of c-myc is commonly observed in a wide range (roughly 70%) of human tumors and intensely associated with the cell proliferation in numerous malignancies, whereas inhibition of c-myc results in cell cycle arrest and decreased cell proliferation ([@B31]; [@B6]). The downstream genes targeted by c-myc for cell cycle regulation are cyclin A, cyclin D, PCNA, p21, p27, PTEN, etc. ([@B14]; [@B11]; [@B13]; [@B54]; [@B33]; [@B37]).

The cyclin A is a member of cyclin family, the transcription of which is tightly regulated and synchronized with cell cycle progression ([@B40]). It promotes both cell cycle G~1~/S and G~2~/M transitions by binding and activating cdk2, a member of the cyclin-dependent kinase family of serine/threonine protein kinases ([@B27]). Complex of cyclin A and cdk2 is required to progress through the S phase and plays important role in G~1~ cell cycle arrest of cancer cells ([@B29]; [@B21]). As another downstream gene of c-myc and also cyclin family member, cyclin D is the major G~1~ phase cyclin and is overexpressed in most cancer cells ([@B5]). Complex of cyclin D and cdk4 is necessary to regulate G~1~/S transition in the cell cycle progression ([@B38]). PCNA is also a c-myc-targeted gene that produces a 36 kD nuclear protein in late G~1~ and S phases for cell proliferation, DNA repair and cell cycle control ([@B41]). Down-regulation of PCNA could induce cell cycle arrest and cell proliferation inhibition of cancer cells (A549; [@B4]). The cdk inhibitors, p21 and p27, are known downstream targets of c-myc and capable of binding to and inhibit the active cyclin/cdk complexes as well as PCNA in the nucleus ([@B11]). Through their binding to cdk2 and cdk4, p21 and p27 have been reported to induce blockade of G~1~/S transitions of cell cycle and then premature senescence in cancer cells ([@B22]). Likewise, by binding to PCNA, p21 blocks the stimulation ability of PCNA to DNA polymerases and leads to DNA replication inhibition and cell cycle arrest ([@B28]; [@B1]). PTEN is a crucial tumor suppressor in many cancer types, the gene of which is negatively regulated by c-myc ([@B54]). It decreases cell proliferation through cell cycle arrest in G~0~/G~1~ phase and is frequently mutated or lost in many kinds of cancers ([@B10]). The decrease of PTEN expression is correlated with poor prognosis of cancers, and vice versa ([@B17]). The above are all c-myc targets associated with G~1~/S transitions of cell cycle and proliferation of cancer cells. In this study, with TB treatment, they showed a consistent expression trend with each other, toward G~1~ cell cycle arrest and proliferation inhibition of A549 cells. Therefore, a mechanism can be proposed that TB directly inhibited the overexpression of *C-MYC* and then transcriptionally regulated the downstream genes as we listed above. It has been found that MAPK and NF-κB are the upstream signaling molecules of *C-MYC*, activation of which positively correlates with c-myc-mediated cell proliferation and cell cycle progression in lung cancer ([@B45]; [@B23]). Other publications reported that tea and its components could inhibit human cell growth and migration by inhibiting MAPK or NF-κB signaling ([@B18]; [@B25]; [@B55]), suggesting the potential importance of those signaling molecules in the role of TB. Therefore, more studies in future are needed to explore MAPK and NF-κB signaling pathways in the c-myc-related mechanism of TB.

The induction of cell cycle arrest is an important mechanism involved in anticancer agents ([@B43]). In particular, cell cycle arrest in the G~1~ phase is of potentially great clinical value, because the G~1~ phase is the most sensitive time point for cancer therapy. A cell cycle restriction point occurs in the mid-G~1~ phase, and after this point, cancer cells become independent of growth factors and become committed to cell division ([@B19]). For example, cancer cells appear to be maximally sensitive to cisplatin in the G~1~ phase and minimally sensitive in peak DNA-synthesis phase, then with a twofold decrease in the S phase ([@B36]). Studies have reported that the down-regulation of c-myc expression can also enhance sensitivity to chemotherapeutic drugs as cisplatin ([@B48], [@B49]). Taken together, TB may not only suppress cancers by itself but also facilitate the effect of chemotherapeutics by increasing cancer cell sensitivity, owing to its c-myc-related mechanism of G~1~ cell cycle arrest.

In the present study, TB induced G~1~ cell cycle arrest and proliferation inhibition of A549 cells by regulation of c-myc and its downstream genes, indicating an anti-NSCLC effect through c-myc-related mechanism (**Figure [8](#F8){ref-type="fig"}**). The results provide evidences that TB dominates and represents the anti-cancer effect of green tea, and that it may facilitate chemotherapy by enhancing cell sensitivity of cancers. We have also evaluated the effect of TB on human embryonic lung fibroblast (HFL1 cell line) by MTT assay and found its cytotoxic dose was upon 1000 μg/ml (data not shown). Within the mentioned dose range between 5 to 300 μg/ml, no toxicity was seen in MTT assay. Therefore, TB induces specific anti-lung cancer effect in this study. Therefore, TB deserves further study in combination with chemotherapeutics for the treatment of NSCLC *in vivo*, contributing to the development of a new anti-cancer agent from green tea.

![**c-myc-related mechanism of TB on A549 cells**.](fphar-08-00075-g008){#F8}
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